TimesSquare Capital Management LLC Invests $16.22 Million in Dianthus Therapeutics, Inc. $DNTH

TimesSquare Capital Management LLC acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 166,357 shares of the company’s stock, valued at approximately $16,216,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DNTH. Persistent Asset Partners Ltd acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $543,000. Global Retirement Partners LLC acquired a new position in shares of Dianthus Therapeutics during the second quarter worth $93,000. SCS Capital Management LLC acquired a new position in shares of Dianthus Therapeutics during the second quarter worth $914,000. Bank of New York Mellon Corp purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at $24,993,000. Finally, State of Wyoming purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at $300,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 16,167 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the sale, the senior vice president owned 3,833 shares in the company, valued at approximately $423,086.54. The trade was a 80.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the transaction, the chief executive officer directly owned 65,292 shares in the company, valued at $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 284,306 shares of company stock worth $29,289,369 in the last quarter. 3.02% of the stock is owned by insiders.

Dianthus Therapeutics Trading Down 0.9%

NASDAQ DNTH opened at $114.86 on Tuesday. Dianthus Therapeutics, Inc. has a 12-month low of $20.31 and a 12-month high of $116.89. The company has a fifty day simple moving average of $98.15 and a two-hundred day simple moving average of $83.52. The stock has a market cap of $6.28 billion, a P/E ratio of -27.68 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DNTH shares. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.